Could engineered fatty particles help prevent AIDS?
September 19, 2011 in HIV & AIDS
Could engineered fatty particles help prevent AIDS? Liposomes block HIV infection in early tests; could be a cost-effective preventive for developing countries
HIV vaccines are in their infancy, and effective microbicides to prevent sexual transmission of HIV still don't exist. Protection is especially needed for women, who make up nearly half of all global cases. Researchers at Children's Hospital Boston envision a new way for women to protect themselves before sex: an applicator filled with specially formulated fatty particles called liposomes.
In tests led by Daniel Kohane, MD, PhD, director of the Laboratory for Biomaterials and Drug Delivery at Children's Hospital Boston, liposomes inhibited HIV infection in cell culture and appeared safe in female mice when injected intravaginally. The findings are reported in the November issue of the journal Biomaterials, published online September 19.
Liposomes are spherical particles with a double outer layer of lipids (fats) and hollow centers. They are relatively easy and cheap to engineer, and thus present a viable option for developing countries, where the cost of anti-HIV drugs bars access for most people.
Liposomes can be filled with drugs or other compounds, but in this case, Kohane and colleagues found, to their surprise, that the liposomes alone were effective in blocking infection.
"We had been planning do much more complex things, like putting ligands on the surface to increase binding to HIV," says Kohane. "It was a surprise that liposomes alone worked so well. Simplicity is always better if liposomes work by themselves, we may not need anything else, and it would be cheaper and potentially much safer."
Kohane and colleagues hope to conduct further tests to better understand how the liposomes are blocking infection. They bind to HIV, perhaps interfering with the virus's ability to fuse with cell membranes, the first step in infection.
"The idea, simplistically, is that liposomes look like cell membranes," says Kohane, "so maybe we could use them as decoys to prevent HIV infection."
Kohane and colleagues formulated a range of liposomes using various naturally occurring and synthetic lipids and screened them systematically in cell cultures. Several formulations showed a good therapeutic profile, protecting the cells from HIV infection without being toxic. Especially effective were liposomes containing cardiolipin, a fat that was first found in animal hearts; performance was further improved by adding a synthetic phospholipid.
Tested in female mice, these formulations caused little or no inflammation, which can compromise the vaginal lining and increase the risk of HIV transmission. Imaging confirmed that the liposomes remained in place or left the body, but did not travel beyond the vagina.
"This research makes an important contribution towards creating a safe and effective form of HIV prevention for women," says Nikita Malavia, PhD, the study's first author, who worked in Kohane's lab and in the lab of Robert Langer, ScD, of MIT. "Women in areas such as sub-Saharan Africa often cannot control their male partners' use of condoms, making them three times more likely to be HIV-positive than men. This technology could enable women to take control in their own hands."
Though some intravaginal compounds are in the pipeline, none are available yet. The advantage of using liposomes is that they are inexpensive, easy to formulate into ointments or gels, and stable for long periods of time, making them a particularly good option in resource-poor settings.
Provided by
Children's Hospital Boston
-
Researchers induce HIV-neutralizing antibodies that recognize HIV-1 envelope protein, lipids
Sep 01, 2009 |
not rated yet |
0
-
Researchers discover new details about HIV-1 entry and infection
Feb 15, 2007 |
not rated yet |
0
-
Long-lasting nerve block could change pain management
Apr 14, 2009 |
not rated yet |
0
-
Chronic HIV-1 infection frequently fails to protect against superinfection
Nov 16, 2007 |
not rated yet |
0
-
Nanotubes transport gene therapy drug into T-cells known to block HIV from entering cells in vitro
Feb 20, 2007 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
AIDS scientists optimistic of AIDS cure, for some
Top AIDS scientists were optimistic Wednesday of finding a cure for the disease that has claimed 30 million lives—but said it might not work for all people.
HIV & AIDS
1 hour ago |
not rated yet |
0
Integrating mental health care into HIV care
The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...
HIV & AIDS
21 hours ago |
not rated yet |
0
After a decade, global AIDS program looks ahead
(AP)—The decade-old law that transformed the battle against HIV and AIDS in developing countries is at a crossroads. The dream of future generations freed from the epidemic is running up against an era ...
HIV & AIDS
May 21, 2013 |
not rated yet |
0
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
HIV & AIDS
May 19, 2013 |
5 / 5 (1) |
0
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
HIV & AIDS
May 18, 2013 |
5 / 5 (2) |
0
Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis
In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...
Research offers promising new approach to treatment of lung cancer
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Overeating learned in infancy, study suggests
In the long run, encouraging a baby to finish the last ounce in their bottle might be doing more harm than good.
Study details genes that control whether tumors adapt or die when faced with p53 activating drugs
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Children of married parents less likely to be obese
Children living in households where the parents are married are less likely to be obese, according to new research from Rice University and the University of Houston.
Researchers rewrite obsolete blood-ordering rules
Johns Hopkins researchers have developed new guidelines—the first in more than 35 years—to govern the amount of blood ordered for surgical patients. The recommendations, based on a lengthy study of blood use at The Johns ...
Sep 20, 2011
Rank: not rated yet
"Dietary, but not topical, alpha-linolenic acid suppresses UVB-induced skin injury in hairless mice when compared with linoleic acid."